21.1.2020 15:20:45 CET | ViroGates | Company Announcement

Company announcement no. 1-2020

Birkerød, 21 January 2020

ViroGates A/S (Nasdaq First North Growth Market Denmark: VIRO), who delivers blood test products, primarily for emergency departments in hospitals, today announces that it has completed the development and regulatory approval (CE-IVD) of its suPARnostic® TurbiLatex product for the ADVIA® Chemistry XPT System from Siemens Healthineers. This is ViroGates’ first validation of the suPARnostic® TurbiLatex product for a Siemens Healthineers instrument. Siemens Healthineers is one of the leading players in the global >60 billion USD in-vitro diagnostics market.

ViroGates’ suPARnostic® TurbiLatex product can now be implemented in clinical routine use at hospitals using the ADVIA XPT systems. The ADVIA XPT is one of the automated clinical chemistry analysers placed in laboratories at the hospitals.  The system can run up to 2,400 samples per hour and work as a fully automated system requiring no manual handling from the blood sampling until results are processed.  The approval of suPARnostic® TurbiLatex for the ADVIA XPT platform complements the previous approvals for the Roche Diagnostics cobas systems.

The suPARnostic® Turbilatex product is a pivotal element in ViroGates’ European expansion strategy with a special focus on the acute care market, valued at approximately 1 billion EUR annually for the suPARnostic® analysis.

CEO Jakob Knudsen, says in a comment: ”We are excited to offer suPARnostic® TurbiLatex to hospitals who are using the ADVIA XPT platform from Siemens Healthineers at their laboratories. Siemens Healthineers is a very active player in the European diagnostics market and several hospitals have requested an approval for the Siemens instrument before proceeding with suPAR implementation. We look forward to continuing the dialogue with these hospitals to support faster and better patient triage decisions to the benefit of patients, hospitals, and payers.”

About the turbidimetric measurement principle: The suPARnostic® TurbiLatex product is based on a technology called turbidimetry that measures the loss of intensity of transmitted light due to the scattering effect of particles suspended in the blood sample. suPARnostic® TurbiLatex is a particle-enhanced turbidimetric assay. The principle of measuring blood samples by using turbidimetry is important in relation to immunoassays. It is the basis of almost all central laboratory clinical chemistry instrument platforms in hospitals.

For further information contact:

CEO Jakob Knudsen

Tel. (+45) 2226 1355, Email: jk@virogates.com

ViroGates A/S - www.virogates.com

Certified Advisor

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, Email: per.lonn@vhcorp.se

About ViroGates

ViroGates is an international medtech company developing and marketing prognostics products to improve patient care, reduce healthcare costs and empower clinical staff in the healthcare sector. Based on more than 600 clinical trials and studies, ViroGates’ suPARnostic® product range supports hospital professionals in making clinical decisions on hospitalization or discharge of acute care patients as well as detecting and assessing the severity of cardiovascular diseases, type 2 diabetes, cancer, etc. suPARnostic® TurbiLatex is available on Siemens ADVIA XPT instruments and Roche Diagnostics’ cobas instruments. ViroGates works with partners to develop solutions for other platforms. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Germany, Spain, and France, while distributors serve other markets. 

This message can be found at https://www.virogates.com/investor/announcements

Disclaimer

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

• Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com

Attachments

• 20200121 ViroGates Comp. ann. 1.pdf